Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 5MEQ K versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 5MEQ K versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K) vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose 5% provides free water and calories, promoting glucose metabolism and cellular energy production; sodium chloride 0.2% provides sodium and chloride ions for maintenance of extracellular fluid volume and osmolality; potassium chloride provides potassium ions essential for nerve conduction, muscle contraction, and acid-base balance.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion, administered at a rate of 100-125 mL/hour in adults, adjusting based on fluid and electrolyte status. Typically provides 5 g dextrose, 34 mEq sodium, 34 mEq chloride, and 5 mEq potassium per liter.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Dextrose: <1 min (rapid cellular uptake); potassium: 6-8 h (redistribution half-life in hyperkalemia). Clinically, potassium's elimination half-life is 12-24 h in normal renal function.
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal: 100% (dextrose is metabolized to CO2 and water; sodium, chloride, and potassium are excreted renally).
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte